|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure显示文摘AIM: To utilize transcatheter arterial steroid injection therapy (TASIT) via the hepatic artery to reduce hepatic macrophage activity in patients with severe acute hepatic failure.METHODS: Thirty-four patients with severe acute hepatic failure were admitted to our hospital between June 2002 to June 2006 providing for the possibility of liver transplantation (LT). Seventeen patients were treated using traditional liver supportive procedures, and the other 17 patients additionally underwent TASIT with 1000 mg methylprednisolone per day for 3 continuous days. RESULTS: Of the 17 patients who received TASIT, 13 were cured without any complications, 2 died, and 2 underwent LT. Of the 17 patients who did not receive TASIT, 4 were self-limiting, 7 died, and 6 underwent LT. Univariate logistic analysis revealed that ascites, serum albumin, prothrombin time, platelet count, and TASIT were significant variables for predicating the prognosis. Multivariate logistic regression analysis using stepwise variable selection showed that prothrombin time, platelet count, and TASIT were independent predictive factors. CONCLUSION: TASIT might effectively prevent the progression of severe acute hepatic failure to a fatal stage of fulminant liver failure. | Kazuhiro Kotoh Munechika Enjoji Makoto Nakamuta Tsuyoshi Yoshimoto Motoyuki Kohjima Shusuke Morizono Shinsaku Yamashita Yuki Horikawa Kengo Yoshimitsu Tsuyoshi Tajima Yoshiki Asayama Kousei Ishigami Masakazu Hirakawa | 2006 | World Journal of Gastroenterology2006，12，41： | 13 |
| 2 | Dietary habits and behaviors associated with nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD)is one of the most frequent causes of health problems in Western(industrialized)countries.Moreover,the incidence of infantile NAFLD is increasing,with some of these patients progressing to nonalcoholic steatohepatitis.These trends depend on dietary habits and life-style.In particular,overeating and its associated obesity affect the development of NAFLD.Nutritional problems in patients with NAFLD include excess intake of energy,carbohydrates,and lipids,and shortages of polyunsaturated fatty acids,vitamins,and minerals.Although nutritional therapeutic approaches are required for prophylaxis and treatment of NAFLD,continuous nutrition therapy is difficult for many patients because of their dietary habits and lifestyle,and because the motivation for treatment differs among patients.Thus,it is necessary to assess the nutritional background and to identify nutritional problems in each patient with NAFLD.When assessing dietary habits,it is important to individually evaluate those that are consumed excessively or insufficiently,as well as inappropriate eating behaviors.Successful nutrition therapy requires patient education,based on assessments of individual nutrients,and continuing the treatment.In this article,we update knowledge about NAFLD,review the important aspects of nutritional assessment targeting treatment success,and present some concrete nutritional care plans which can be applied generally. | Kenichiro Yasutake Motoyuki Kohjima Kazuhiro Kotoh Manabu Nakashima Makoto Nakamuta Munechika Enjoji | 2014 | World Journal of Gastroenterology2014，20，7： | 9 |
| 3 | A new treatment strategy for acute liver failure显示文摘Acute liver failure (ALF) is a syndrome def ined by coa g ulopathy and encephalopathy and no effective treat ments have been established, except for liver transplantation. However, considering the limited supply of donors, we should endeavor to prevent the progre ssion of this syndrome in its early stage to improve the prognosis of patients with ALF. Recently, several authors have reported that over-activation of intrahepatic macrophages plays an important role in the progression of ALF and we have developed a new treatment method, transcatheter arterial steroid injection therapy (TASIT), to suppress macrophage activation. We have now used TASIT for 5 years and have found that TASIT is effective for patients with over-activation of macrophages in the liver but not for those with les ser activation of macrophages. Therefore, to identify the most appropriate patients for TASIT, we tried to categorize patients with ALF or acute liver injury according to markers for the degree of intrahepatic macrophage activation. This approach was helpful to select the appro-priate treatment including liver transplantation. We believe that it is essential to analyze disease progression in each patient before selecting the most appropriate treatment. | Kazuhiro Kotoh Masaki Kato Motoyuki Kohjima Makoto Nakamuta Munechika Enjoji | 2010 | World Journal of Hepatology2010，2，11： | 8 |
| 4 | Scattered and rapid intrahepatic recurrences after radio frequency ablation for hepatocellular carcinoma显示文摘AIM: To evaluate a series of patients with hepatocellular carcinoma (HCC) treated with several different protocols and devices.METHODS: We treated 138 patients [chronic hepatitis/liver cirrhosis (Child-Pugh A/B/C), 3/135 (107/25/3)]with two different devices and protocols: cool-tip needle [initial ablation at 60 W (standard method) (n=37)or at 40 W (modified method) (n = 28)] or; ablation with a LeVeen needle using a standard single-step, full expansion (single-step) method (n = 39) or a multi-step,incremental expansion (multi-step) method.RESULTS: Eleven patients experienced rapid and scattered recurrences 1 to 7 mo after the ablation. Nine patients were treated by the cool-tip original protocol (60 W) (9/37=24%) and the other two by the LeVeen single-step method (2/39=5%). The location of the recurrence was surrounding and limited to the site of ablation segment in three cases, and spread over one lobule or both lobules in the other eight cases. There was no recurrence in the patients treated with the modified cool-tip modified method (40 W) or the LeVeen multi-step method.CONCLUSION: There is a risk of rapid and scattered recurrence after RFA, especially when the standard cooltip procedure is used. Because such recurrence would worsen the prognosis, we recommend that modified protocols for the cool-tip and LeVeen needle methods should be used in clinical practice. | Kazuhiro Kotoh Munechika Enjoji Eiichirou Arimura Shusuke Morizono Motoyuki Kohjima Hironori Sakai Makoto Nakamuta | 2005 | World Journal of Gastroenterology2005，11，43： | 7 |
| 5 | Baseline characterization of patients aged 70 years and above with hepatocellular carcinoma显示文摘AIM: To characterize the baseline profiles of patients aged 70 years and above with hepatocellular carcinoma (HCC).METHODS: A series of 127 consecutive patients with HCC were enrolled between 2000 and 2004, and none of them had been diagnosed as having HCC previously. Baseline profiles, including parameters of hepatic function such as serum transaminase and prothrombin time [PT (% activity)] were compared between patients aged ≥70 and <70 years.RESULTS: Patients ≥70 years old showed significantly lower levels of aspartate aminotransferase (P = 0.04)and alanine aminotransferase (P = 0.01), and significantly higher PTs (P= 0.04) and platelet counts (P = 0.02).Concomitantly, among ≥70-year-old patients, HCC was more common in non-cirrhotics, whereas among patients <70 years old, HCC was more common in cirrhotics. There was no significant difference between the groups in the number or size of tumors.CONCLUSION: Older HCC patients showed less inflammation and better preservation of hepatic function, indicating that not only cirrhotic patients but also noncirrhotic patients should be considered as a high-risk group among the elderly. | Makoto Nakamuta Shusuke Morizono Motoyuki Kohjima Kazuhiro Kotoh Munechika Enjoji | 2005 | World Journal of Gastroenterology2005，11，47： | 6 |
| 6 | Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virusinfected liver显示文摘AIM:To investigate the relationship between the ironmetabolism-related gene expression profiles and efficacy of antiviral therapy in chronic hepatitis C patients.METHODS:The hepatic expression profile of ironmetabolism-related genes was analyzed and its association with virological response to pegylated-interferon plus ribavirin combination therapy was evaluated.A hundred patients with chronic hepatitis C(genotype1b,n = 50; genotype 2,n = 50) were enrolled and retrospectively analyzed.Liver biopsy samples were subjected to quantitative polymerase chain reaction for iron-metabolismrelated genes and protein expression(Western blotting analysis) for ferroportin.As a control,normal liver tissue was obtained from 18 living donors of liver transplantation.Serum hepcidin level was measured by sensitive liquid chromatography/electrospray ionization tandem mass spectrometry.RESULTS:Iron overload is associated with liver damage by increasing oxidative stress and hepatitis C virus(HCV)is reported to induce iron accumulation in hepatocytes in vivo.Conversely,iron administration suppresses HCV replication in vitro.Therefore,the association between HCV infection and iron metabolism remains unclear.Compared with controls,patients had significantly higher gene expression for transferrin,iron-regulatoryproteins 1 and 2,divalent metal transporter 1,and ferroportin,but similar for transferrin receptors 1 and2,and hepcidin.When the expression profiles were compared between sustained virological response(SVR)and non-SVR patients,the former showed significantly lower transcription and protein expression of hepcidin and ferroportin.Expression of hepcidin-regulating genes,BMPR1,BMPR2,and hemojuvelin,was significantly increased,whereas BMP2 was decreased in HCV-infected liver.BMPR2 and hemojuvelin expression was significantly lower in the SVR than non-SVR group.HCV infection affects the expression of iron-metabolism-related genes,leading to iron accumulation in hepatocytes.CONCLUSION:Decreased expression of hepcidin and ferroportin in SVR patients indicates the importance of hepatocytic iron retention for viral response during pegylated-interferon plus ribavirin treatment. | Motoyuki Kohjima Tsuyoshi Yoshimoto Munechika Enjoji Nobuyoshi Fukushima Kunitaka Fukuizumi Tsukasa Nakamura Miho Kurokawa Nao Fujimori Yusuke Sasaki Yasushi Shimonaka Yusuke Murata Susumu Koyama Ken Kawabe Kazuhiro Haraguchi Yorinobu Sumida Naohiko Harada Masaki Kato Kazuhiro Kotoh Makoto Nakamuta | 2015 | World Journal of Gastroenterology2015，21，11： | 4 |
| 7 | Antithrombin Ⅲ injection via the portal vein suppresses liver damage显示文摘AIM:To investigate the effects of antithrombin Ⅲ(AT Ⅲ) injection via the portal vein in acute liver failure.METHODS:Thirty rats were intraperitoneally challenged with lipopolysaccharide(LPS) and D-galactosamine(GalN) and divided into three groups:a control group;a group injected with AT Ⅲ via the tail vein;and a group injected with AT Ⅲ via the portal vein.AT Ⅲ(50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN.Serum levels of inflammatory cytokines and fibrin degradation products,hepatic fibrin deposition,and hepatic mRNA expression of hypoxiarelated genes were analyzed.RESULTS:Serum levels of alanine aminotransferase,tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT Ⅲ injection compared with tail vein injection,and control rats.Portal vein AT Ⅲ injection reduced liver cell destruction and decreased hepatic fibrin deposition.This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1.CONCLUSION:A clinically acceptable dose of AT Ⅲ injection into the portal vein suppressed liver damage,probably through its enhanced anticoagulant and antiinflammatory activities. | Masayuki Miyazaki Masaki Kato Masatake Tanaka Kosuke Tanaka Shinichiro Takao Motoyuki Kohjima Tetsuhide Ito Munechika Enjoji Makoto Nakamuta Kazuhiro Kotoh Ryoichi Takayanagi | 2012 | World Journal of Gastroenterology2012，18，16： | 2 |
| 8 | SREBP-1c, regulated by the insulin and AMPK signaling pathways, playsa role in nonalcoholic fatty liver disease显示文摘 | Motoyuki Kohjima Nobito Higuchi Masaki Kato Kazuhiro Kotoh Tsuyoshi Yoshimoto Tatsuya Fujino Masayoshi Yada Ryoko Yada Naohiko Harada Munechika Enjoji Ryoichi Takayanagi Makoto Nakamuta | 2008 | International Journal of Molecular Medicine2008，，4： | 2 |
| 9 | Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholicfatty liver disease and its association with insulin resistance and glucose metabolism显示文摘 | Masayuki Miyazaki Masaki Kato Kosuke Tanaka Masatake Tanaka Motoyuki Kohjima Kazuhiko Nakamura Munechika Enjoji Makoto Nakamuta Kazuhiro Kotoh Ryoichi Takayanagi | 2012 | Molecular Medicine Reports2012，，3： | 2 |
| 10 | Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver dis- ease显示文摘 | Kohjima M Enjoji M Higuchi N | 2007 | Int J Mol Med2007，20，3： | 1 |
| 11 | Add‐on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C显示文摘 | Motoyuki Kohjima Munechika Enjoji Tsuyoshi Yoshimoto Ryoko Yada Tatsuya Fujino Yoko Aoyagi Nobuyoshi Fukushima Kunitaka Fukuizumi Naohiko Harada Masayoshi Yada Masaki Kato Kazuhiro Kotoh Manabu Nakashima Naoya Sakamoto Yasuhito Tanaka Makoto Nakamuta | 2012 | Virol2012，，2： | 1 |
| 12 | SREBP-1 c, regulated by theinsulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease 显示文摘 | Kohjima M Higuchi N Kato M | 2008 | Int J Mol Med2008，21，4： | 1 |
| 13 | SREBP-1c, regula ted by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease 显示文摘 | Kohjima M Higuchi N Kato M | 2008 | Int J Mol Med2008，21，4： | 1 |
| 14 | The PB1 domain and the PC motif-containing region are structurally similar protein binding modules显示文摘 | KOHJIMA M OGURA K | 2003 | EMBO J2003，22，19： | 1 |
| 15 | NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalco- holic fatty liver disease显示文摘 | Enjoji M Machida K Kohjima M | 2010 | Lipids Health Dis2010，9，： | 1 |
| 16 | Epigallocatechin-3-gallate,a polyphenol component of green tea,suppresses both collagen production and collagenase activity in hepatic stellate cells显示文摘 | Nakamuta M Higashi N Kohjima M | 2005 | Int J Mol Med2005，16，4： | 1 |
| 17 | Therapeutic effect of ARBs on insulin resistance and liver inju- ry in patients with NAFLD and chronic hepatitis C: a pilot study显示文摘 | Enjoji M Kotoh K Kato M Higuchi N Kohjima M Nakashima M | 2008 | Int J Mol Med2008，22，4： | 1 |
| 18 | Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism显示文摘 | KOHJIMA M ENJOJI M YADA R | 2015 | Liver Int2015，35，3： | 1 |
| 19 | Re-evaluation of fatty acid metabolismrelated gene expression in non-alcoholic fatty liver disease显示文摘 | KOHJIMA M | 2007 | Int J Mol Med2007，20，3： | 1 |
| 20 | Fasudil hydrochloride hydrate,a Rho-kinase(ROCK)inhibitor,suppresses collagen production and enhances collagenase activity in hepatic stellate cells显示文摘 | Fukushima M Nakamuta M Kohjima M | 2005 | Liver International2005，25，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员